Q-omics provides the consensus-scored TRIM51BP profile across patient tissues and cancer cell-line models. TRIM51BP expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TRIM51BP is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, TRIM51BP RNA expression shows 8,247 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, LUAD, and TGCT as cancer lineages where TRIM51BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM51BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM51BP survival associations across molecular data types. TRIM51BP RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM51BP RNA expression–survival associations across cancer types. High TRIM51BP expression shows unfavorable associations in COAD, UCS, READ, UCEC and DLBC, but favorable associations in SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TRIM51BP RNA expression.
This table summarizes TRIM51BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM51BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM51BP shows lower tumor expression in THCA and higher tumor expression in LUAD and KIRC. The LUAD box plot shows higher TRIM51BP RNA expression in tumor versus normal tissue (log2 FC = +0.549, t-test p < 0.001).
This table shows molecular features associated with TRIM51BP in patient tissues and cancer cell lines. In patient samples, TRIM51BP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
